Michael York
Net worth: 59 629 $ as of 31/05/2023
Profile
Michael York served as President & Chief Executive Officer at Sente, Inc. from 2013 to 2014.
He was Vice President-Specialty & Rare Disease Unit at Amylin Pharmaceuticals, Inc. He also served as Vice President-Global Business Development at Orexigen Therapeutics, Inc. from 2015 to 2018.
From 2018 to 2021, he was Vice President-Development & Commercial Strategy at PhaseBio Pharmaceuticals, Inc. He served as President & Chief Executive Officer at SENTÉ Labs.
In 2021, he became President, CEO, CFO, Secretary & Treasurer at Metacrine, Inc. Mr. York received his undergraduate degree from San Diego State University and his MBA from the University of Redlands.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
METACRINE INC
0.25% | 03/02/2023 | 107,054 ( 0.25% ) | 59 629 $ | 31/05/2023 |
Former positions of Michael York
| Companies | Position | End |
|---|---|---|
| METACRINE, INC. | Chief Executive Officer | 24/03/2023 |
| PHASEBIO PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/11/2021 |
| OREXIGEN THERAPEUTICS, INC. | Corporate Officer/Principal | 01/06/2018 |
| Sente, Inc. | Chief Executive Officer | 01/12/2014 |
| SENTÉ Labs | Chief Executive Officer | - |
Training of Michael York
| San Diego State University | Undergraduate Degree |
| University of Redlands | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| PHASEBIO PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 5 |
|---|---|
Amylin Pharmaceuticals, Inc.
 Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amylin Pharmaceuticals, Inc. develops and commercializes medicines for diabetes, obesity, and cardiovascular diseases. The company was founded on September 29, 1987 by Howard E. Greene, Jr. and is headquartered in San Diego, CA. | Health Technology |
Orexigen Therapeutics, Inc.
 Orexigen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Orexigen Therapeutics, Inc. is a biopharmaceutical company, which focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its primary activities include recruiting personnel, conducting research and development, including clinical trials, raising capital, and preparing for the marketing and commercialization of its product, contrave. The company was founded by Eckard Weber in September 2002 and is headquartered in La Jolla, CA. | Health Technology |
| Sente, Inc. | Technology Services |
| SENTÉ Labs | |
| Metacrine, Inc. |
- Stock Market
- Insiders
- Michael York
